表紙
市場調查報告書
商品編碼
1000814

腿不安綜合徵(中樞神經系統):藥物開發中(2021)

Restless Legs Syndrome (Central Nervous System) - Drugs in Development, 2021

出版日期: | 出版商: Global Markets Direct | 英文 57 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

腿不安綜合症(RLS),又稱威利斯埃克博姆病(WED),是一種神經系統疾病,會影響腿部並引起腿部活動的衝動,小腿和腿部發癢,疼痛,刺痛的感覺和抽筋,病因包括年齡。治療方法包括肌肉鬆弛劑,安眠藥和麻醉劑。

本報告調查了針對不安腿綜合徵(中樞神經系統),全球治療情況,管線治療評論,開發,管線產品藥物概況,領先公司的開發中的藥物我們提供了有關諸如以下方面的評論和有關管線治療的最新新聞:腿不安綜合症。

目錄

  • 簡介
  • 直接向世界市場報告的下屬的報告
  • 腿不安綜合症-概述
  • 腿不安綜合症-治療的發展
  • 管道概述
  • 公司管道
  • 公司正在開發的產品
  • 不安腿綜合症治療
  • 按目標評估
  • 通過作用機制進行評估
  • 按管理途徑評估
  • 按分子類型評估
  • 腿不安綜合症-參與治療開發的公司
  • Axim生物技術公司
  • Bioprojet SCR
  • 久光製藥有限公司
  • 綠葉製藥集團有限公司
  • NLS製藥集團
  • Omeros Corp
  • Relmada Therapeutics Inc
  • Seelos Therapeutics,Inc.
  • Serina Therapeutics Inc
  • Vifor Pharma Ltd
  • 腿不安綜合症-藥物簡介
  • (大麻二酚+屈大麻酚)-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 阿普利多富馬酸酯-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • BP-1.4979-藥品簡介
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 羧甲基鐵蛋白藥物譜
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • LY-03009-藥品簡介
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • NLS-2-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • OMS-527-藥物檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • REL-1017-藥物檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 鹽酸羅匹尼羅CR-藥物概況
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • SER-214-藥物檔案
  • 產品概述
  • 作用機理
  • 研究與開發的進展
  • 不安腿綜合症休眠計劃
  • 不安腿綜合症停產的產品
  • 腿不安綜合症-產品開發里程碑
  • 精選新聞和新聞稿
  • 2021年1月4日:綠葉製藥集團:LY03009在澳大利亞啟動了I期臨床試驗
  • 2014年10月23日:久光宣佈了HP-3000在日本的II期臨床試驗結果(經皮系統治療特發性躁動性腿綜合徵)
  • 2013年3月25日:美國專利商標局授予Serina Therapeutics重大專利,涵蓋了帕金森氏病和不安腿綜合徵的關鍵臨床候選藥物
  • 2008年10月16日:Neurogen宣佈兩項關於腿部不安綜合症和Aprindre治療帕金森氏病的II期臨床試驗的陽性結果
  • 附錄
  • 調查方法
  • 調查範圍
  • 二次調查
  • 初步調查
  • 專家小組驗證
  • 聯繫我們
  • 免責聲明
目錄
Product Code: GMDHC12761IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, provides an overview of the Restless Legs Syndrome (Central Nervous System) pipeline landscape.

Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is a disorder of the part of the nervous system that affects the legs and causes an urge to move them. Symptoms include itching, pain, a creepy-crawly feeling and cramping in the calf's or legs. Predisposing factor includes age. Treatment includes muscle relaxants, sleep medications and narcotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restless Legs Syndrome - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Restless Legs Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restless Legs Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Restless Legs Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 3 and 2 respectively.

Restless Legs Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Restless Legs Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Restless Legs Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Restless Legs Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Restless Legs Syndrome (Central Nervous System)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Restless Legs Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Restless Legs Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Global Markets Direct Report Coverage
  • Restless Legs Syndrome - Overview
  • Restless Legs Syndrome - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Restless Legs Syndrome - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Restless Legs Syndrome - Companies Involved in Therapeutics Development
  • Axim Biotechnologies Inc
  • Bioprojet SCR
  • Hisamitsu Pharmaceutical Co Inc
  • Luye Pharma Group Ltd
  • NLS Pharma Group
  • Omeros Corp
  • Relmada Therapeutics Inc
  • Seelos Therapeutics, Inc.
  • Serina Therapeutics Inc
  • Vifor Pharma Ltd
  • Restless Legs Syndrome - Drug Profiles
  • (cannabidiol + dronabinol) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • aplindore fumarate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BP-1.4979 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ferric carboxymaltose - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-03009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NLS-2 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OMS-527 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REL-1017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ropinirole hydrochloride CR - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SER-214 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Restless Legs Syndrome - Dormant Projects
  • Restless Legs Syndrome - Discontinued Products
  • Restless Legs Syndrome - Product Development Milestones
  • Featured News & Press Releases
  • Jan 04, 2021: Luye Pharma Group: LY03009 commenced phase I clinical trial in Australia
  • Oct 23, 2014: Hisamitsu Announces the results of Phase II clinical study of HP-3000 in Japan (a transdermal system for the treatment of idiopathic restless legs syndrome)
  • Mar 25, 2013: US Patent and Trademark Office awards Serina Therapeutics key patent covering its lead clinical candidate for Parkinson's disease and restless leg syndrome
  • Oct 16, 2008: Neurogen Announces Positive Top-Line Results From Two Phase II Trials For Aplindore In Restless Legs Syndrome And Parkinson's Disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Restless Legs Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Restless Legs Syndrome - Pipeline by Axim Biotechnologies Inc, 2021
  • Restless Legs Syndrome - Pipeline by Bioprojet SCR, 2021
  • Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co Inc, 2021
  • Restless Legs Syndrome - Pipeline by Luye Pharma Group Ltd, 2021
  • Restless Legs Syndrome - Pipeline by NLS Pharma Group, 2021
  • Restless Legs Syndrome - Pipeline by Omeros Corp, 2021
  • Restless Legs Syndrome - Pipeline by Relmada Therapeutics Inc, 2021
  • Restless Legs Syndrome - Pipeline by Seelos Therapeutics, Inc., 2021
  • Restless Legs Syndrome - Pipeline by Serina Therapeutics Inc, 2021
  • Restless Legs Syndrome - Pipeline by Vifor Pharma Ltd, 2021
  • Restless Legs Syndrome - Dormant Projects, 2021
  • Restless Legs Syndrome - Discontinued Products, 2021

List of Figures

  • Number of Products under Development for Restless Legs Syndrome, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Stage and Molecule Types, 2021